Evidence map›Paper›PMID 35924928›Full record

ArticleAntimicrobial agents and chemotherapy2022

Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.

Kamrul Islam, Fekade B Sime, Steven C Wallis, Michelle J Bauer, Saiyuri Naicker, Hayoung Won, Hosam M Zowawi, Md Abu Choudhury, Tahmina Shirin, Zakir H Habib and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. DynamicAntibiotics (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Kamrul IslamUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-5968-7068
Fekade B SimeUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-4061-2063
Steven C WallisUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Michelle J BauerUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Saiyuri NaickerUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Hayoung WonUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Hosam M ZowawiUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Md Abu ChoudhurySchool of Nursing, Midwifery & Public Health, University of Canberragrid.1039.b, Bruce, Australian Capital Territory, Australia.
Tahmina ShirinInstitute of Epidemiology, Disease Control and Research, Mohakhali, Dhaka, Bangladesh.
Zakir H HabibInstitute of Epidemiology, Disease Control and Research, Mohakhali, Dhaka, Bangladesh.
Patrick N A HarrisUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-2895-0345
Meerjady S FloraDirectorate General of Health Services, Mohakhali, Dhaka, Bangladesh.
Jason A RobertsUniversity of Queenslandgrid.1003.2 Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0001-6218-435X
The University of Queensland · AUInstitute of Epidemiology, Disease Control and Research · BDDirectorate General of Health Services · BDUniversity of Canberra · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenems are recommended for the treatment of urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing, multidrug-resistant Escherichia coli

Indexed as

AmikacinEscherichia coliAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCarbapenemsMeropenemMicrobial Sensitivity TestsPiperacillinPiperacillin, Tazobactam Drug CombinationAmikacinAnti-Bacterial Agentsbeta-Lactamasesbeta-LactamsCarbapenemsMeropenemPiperacillinPiperacillin, Tazobactam Drug Combinationcombination therapydynamic hollow fiber infection modelEscherichia coliextended-spectrum β-lactamase (ESBL)piperacillin-tazobactam and amikacinurosepsis

Identifiers

PMID35924928
PMCPMC9487465
OpenAlexW4289844288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.